Clinical trials: Circulatory Function
Bradycardia
Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker
The IBSY04 clinical investigation is an European, prospective, multi-centre, non-randomized, longitudinal study.
- Trial name
- DREAM (NCT01537718)
- Testing
- REPLY 200
- Where
- 5 sites in France, Spain
- Volunteers
- 40 people
- Sponsor
- LivaNova
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Stroke
A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial
Current literature has only limited information on the natural history of acute ischemic stroke from large vessel occlusion in a stroke cohort who presents within 8 hours from symptom onset, particularly on 90 day functional…
- Trial name
- FIRST (NCT01092819)
- Testing
- Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies
- Where
- 3 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Penumbra Inc.
Diabetes Mellitus, Type 2, Atherosclerosis
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.
- Conditions
- Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
- Trial name
- NCT00995930
- Testing
- ACZ885
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation (AF)
Blood Pressure Monitor (TH-75) Atrial Fibrillation Detection Function Clinical Trial
This study evaluates the accuracy of a blood pressure monitor in detecting atrial fibrillation by comparing its results with a standard diagnostic method.
- Trial name
- NCT07442175
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Andon Health Co., Ltd
Health, Subjective, Gastrointestinal Dysfunction
Personal Lifestyle Engine (PLX) - Personal Lifestyle Medicine Center (PLMC)
It has been suggested that the best medicine should include four principles (4P) - Medicine should be personalized, predictive, preventative and participatory.
- Conditions
- Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases
- Trial name
- NCT04007939
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Multiple Myeloma
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb).
- Trial name
- DREAMM12 (NCT04398745)
- Testing
- Belantamab mafodotin
- Where
- 4 sites in Greece, South Korea
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
The 5-milligram (mg) dose of prasugrel in low body weight (LBW) patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg dose in higher body weight (HBW) patients.
- Trial name
- FEATHER (NCT01107925)
- Testing
- prasugrel, clopidogrel
- Where
- 6 sites in United States, Ireland and 2 more
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical…
- Trial name
- NCT07749170
- Testing
- Endovascular Thrombectomy, Medical Management
- Where
- 7 sites in United States
- Volunteers
- 250 people
- Sponsor
- Penumbra Inc.
Coronary Artery Disease
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
- Trial name
- GENERATIONS (NCT01107912)
- Testing
- prasugrel, clopidogrel
- Where
- 7 sites in United States, Ireland and 2 more
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Functional Magnetic Resonance Imaging
A Study of Two Methodologies for Measuring Blood Flow in the Brain in Response to Non-Drug Stimuli (P08085/MK-0000-180)
This study will identify a dose of ferumoxytol that can reliably detect changes in blood flow/volume in response to non-drug stimuli.
- Trial name
- NCT01244282
- Testing
- fMRI with sensory stimulation
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mitral Regurgitation, Valve Heart Disease
SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation
This study is a prospective, single-arm, multi-center feasibility clinical study of the SATURN TA System for the treatment of NYHA Class ≥ II patients with severe functional mitral regurgitation who are not suitable for surgical…
- Conditions
- Mitral Regurgitation, Valve Heart Disease, Heart Valve Diseases, Mitral Valve Disease
- Trial name
- NCT04464876
- Testing
- SATURN TA System
- Where
- 3 sites in Denmark, Hungary and 1 more
- Volunteers
- 20 people
- Sponsor
- InnovHeart
Fabry Disease
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single dose of 150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects with normal renal function and to subjects…
- Trial name
- NCT01730469
- Testing
- AT1001 150 mg
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Diabetes Mellitus, Type 2, Plasma Volume
A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to evaluate the effects of canagliflozin on plasma volume and renal parameters in patients with Type 2 Diabetes Mellitus who are currently taking metformin and being treated for high blood pressure.
- Trial name
- NCT01483781
- Testing
- Canagliflozin
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2, Essential Hypertension
Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea
This study was designed to evaluate the anti-hypertensive efficacy of lacidipine in hypertensives with Type 2 diabetes and effectiveness on endothelial cell function in Korean population.
- Trial name
- NCT00328965
- Testing
- Lacidipine
- Sponsor
- GlaxoSmithKline
Congestive Heart Failure
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)
A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function
- Trial name
- NCT00634712
- Testing
- Candesartan
- Volunteers
- 734 people
- Sponsor
- AstraZeneca
Heart Failure
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure.
- Trial name
- 8282-Reduced (NCT06979375)
- Testing
- CDR132L
- Where
- 92 sites in Australia, Czechia and 8 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Stroke, Hand Function
Hand Training & Brain Changes
10 participants with upper-limb impairment will be recruited from community sources. They will be invited to participate in a 15-day trial involving the IRegained device.
- Trial name
- NCT05811819
- Testing
- Treatment using the MyHand System
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- IRegained Inc.
Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes
This is a phase 2, multicenter, randomized, double-blind (within dose), placebo controlled, parallel-group, dose-range finding study to evaluate the efficacy and safety of TF0023 spray versus placebo in functional improvement of…
- Trial name
- TF0023 (NCT02785120)
- Testing
- TF0023
- Where
- 24 sites in United States
- Volunteers
- 225 people
- Sponsor
- Techfields Inc